Sorafenib and Regorafenib in HBV- Or HCV-positive Hepatocellular Carcinoma Patients: Analysis of RESORCE and SHARP Trials
Digestive and Liver Disease - Netherlands
doi 10.1016/j.dld.2017.04.022
Full Text
Open PDFAbstract
Available in full text
Date
August 1, 2017
Authors
Publisher
Elsevier BV